Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sexually Transmitted Infections01:26

Sexually Transmitted Infections

175
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
175

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nasal and Ocular Immunization with Bacteriophage Virus-like Particle Vaccines Elicits Distinct Systemic and Mucosal Antibody Profiles.

Vaccines·2025
Same author

Immunization Against <i>Chlamydia trachomatis</i> Polymorphic Membrane Protein D Tetrapeptide Motifs Limits Early Female Reproductive Tract Infection in a Mouse Model.

Vaccines·2025
Same author

Two doses of Qβ virus like particle vaccines elicit protective antibodies against heroin and fentanyl.

NPJ vaccines·2025
Same author

Pathogenic and Protective Roles of Neutrophils in <i>Chlamydia trachomatis</i> Infection.

Pathogens (Basel, Switzerland)·2025
Same author

Web Exclusive. Annals On Call - Kratom: A Substance Physicians Should Be Aware Of.

Annals of internal medicine·2024
Same author

A two-dose regimen of Qβ virus-like particle-based vaccines elicit protective antibodies against heroin and fentanyl.

bioRxiv : the preprint server for biology·2024

Related Experiment Video

Updated: May 7, 2025

Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

12.8K

Progress towards effective vaccines for Chlamydia trachomatis.

Amanda L Collar1, Kathryn M Frietze2

  • 1Department of Internal Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

Current Opinion in Infectious Diseases
|January 2, 2025
PubMed
Summary
This summary is machine-generated.

Developing an effective vaccine for Chlamydia trachomatis (Ct) infection is nearing reality. Recent trials show promise for the CTH522 vaccine, with ongoing research exploring new approaches for Ct vaccine development.

More Related Videos

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

1.6K
Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis
10:35

Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis

Published on: January 30, 2020

6.6K

Related Experiment Videos

Last Updated: May 7, 2025

Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

12.8K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

1.6K
Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis
10:35

Markerless Gene Deletion by Floxed Cassette Allelic Exchange Mutagenesis in Chlamydia trachomatis

Published on: January 30, 2020

6.6K

Area of Science:

  • Infectious Diseases
  • Vaccinology
  • Immunology

Background:

  • Sexually transmitted Chlamydia trachomatis (Ct) infections pose a significant global health challenge.
  • Effective vaccines for Ct have been a long-standing research goal, with limited success to date.
  • Understanding the natural immune response to Ct is crucial for vaccine design.

Purpose of the Study:

  • To review recent advancements in the development of vaccines against Chlamydia trachomatis.
  • To highlight promising vaccine candidates and emerging research strategies.

Main Methods:

  • Review of recent clinical trial data, focusing on the CTH522 vaccine.
  • Analysis of preclinical research exploring novel antigens, adjuvants, and administration routes.
  • Synthesis of current understanding of immune responses to Ct infection.

Main Results:

  • The first-in-human Chlamydia trachomatis vaccine, CTH522, reported Phase I/IIB trial results in 2019.
  • CTH522 and its derivatives are identified as leading vaccine candidates.
  • Preclinical development includes targeting non-MOMP antigens and utilizing novel adjuvants and administration routes.

Conclusions:

  • Vaccine approval for Chlamydia trachomatis is closer than previously anticipated.
  • Careful consideration of implementation strategies is vital for successful clinical translation of Ct vaccines.